Samyang Biopharm USA, Inc. is the established subsidiary of Samyang Holdings Corporation (Republic of Korea) specializing in global biologics development in oncology and rare disease. We seek global in-license rights to late preclinical to Phase 1 antibodies, antibody drug conjugates and recombinant proteins for clinical development with a focus on US Phase 1 trials.
